Clinical Data Inc. entered a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for multiple myeloma and other B-cell cancers, but the deal might be more strategic than lucrative. (BioWorld Today) Read More
